Exploring Metabolic Adaptation of Microbials to Antibiotics

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Microbiology and Ecological Metabolomics".

Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 2824

Special Issue Editor


E-Mail Website
Guest Editor
Cellular Biochemistry & Metabolomics, Institute of Biochemistry, University of Greifswald, Felix-Hausdorff-Strasse 4, 17489 Greifswald, Germany
Interests: metabolic profiling; microbial metabolomics; eukaryotic metabolism; host-pathogen interactions; mass spectrometry; NMR spectroscopy; gas chromatography; liquid chromatography; sampling protocols in metabolomics

Special Issue Information

Dear Colleagues,

We are pleased to announce a Special Issue of the journal Metabolites dedicated to approaches to investigate the metabolic adaptation of bacterial pathogens towards antibiotics.

The rapid development of bacterial resistance to antibiotics is among the most severe threats to human health. In the last 40 years, only two new classes of antibiotics have been introduced. Facing an increasing occurrence of pathogenic bacteria resistant to known antibiotics, the search for new antimicrobial compounds with possible new modes of action is an emerging field of research. Knowledge of the mechanisms with which bacteria cope with antimicrobial stress conditions is essential to understanding the modes of action and possible loopholes in which pathogens can escape the impact of antibiotics. Since naturally occurring molecules, in most cases, have many issues preventing their direct introduction to the clinic, the analysis of promising antimicrobial derivatives using metabolomics methods could pave the way to finding new antibiotics. This Special Issue aims to incorporate novel and review papers from a wide range of key topics in the field of antibiotics research.

Prof. Dr. Michael Lalk
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antibiotics
  • novel bioactive compounds
  • modes of action
  • cellular metabolic adaptation
  • antibiotic resistance

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 7722 KiB  
Article
In Vitro Assessment of Antistaphylococci, Antitumor, Immunological and Structural Characterization of Acidic Bioactive Exopolysaccharides from Marine Bacillus cereus Isolated from Saudi Arabia
by Samy Selim, Mohammed S. Almuhayawi, Mohanned Talal Alharbi, Mohammed K. Nagshabandi, Awadh Alanazi, Mona Warrad, Nashwa Hagagy, Ahmed Ghareeb and Abdallah S. Ali
Metabolites 2022, 12(2), 132; https://doi.org/10.3390/metabo12020132 - 01 Feb 2022
Cited by 10 | Viewed by 2316
Abstract
A strain of Bacillus cereus was isolated from the Saudi Red Sea coast and identified based on culture features, biochemical characteristics, and phylogenetic analysis of 16S rRNA sequences. EPSR3 was a major fraction of exopolysaccharides (EPS) containing no sulfate and had [...] Read more.
A strain of Bacillus cereus was isolated from the Saudi Red Sea coast and identified based on culture features, biochemical characteristics, and phylogenetic analysis of 16S rRNA sequences. EPSR3 was a major fraction of exopolysaccharides (EPS) containing no sulfate and had uronic acid (28.7%). The monosaccharide composition of these fractions is composed of glucose, galacturonic acid, and arabinose with a molar ratio of 2.0: 0.8: 1.0, respectively. EPSR3 was subjected to antioxidant, antitumor, and anti-inflammatory activities. The results revealed that the whole antioxidant activity was 90.4 ± 1.6% at 1500 µg/mL after 120 min. So, the IC50 value against DPPH radical found about 500 µg/mL after 60 min. While using H2O2, the scavenging activity was 75.1 ± 1.9% at 1500 µg/mL after 60 min. The IC50 value against H2O2 radical found about 1500 µg/mL after 15 min. EPSR3 anticytotoxic effect on the proliferation of (Bladder carcinoma cell line) (T-24), (human breast carcinoma cell line) (MCF-7), and (human prostate carcinoma cell line) (PC-3) cells. The calculated IC50 for cell line T-24 was 121 ± 4.1 µg/mL, while the IC50 for cell line MCF-7 was 55.7 ± 2.3 µg/mL, and PC-3 was 61.4 ± 2.6 µg/mL. Anti-inflammatory activity was determined for EPSR3 using different methods as Lipoxygenase (LOX) inhibitory assay gave IC50 12.9 ± 1.3 µg/mL. While cyclooxygenase (COX-2) inhibitory test showed 29.6 ± 0.89 µg /mL. EPSR3 showed potent inhibitory activity against methicillin-resistant Staphylococcus aureus (MRSA) and coagulase-negative staphylococci. The exposure times of EPSR3 for the complete inhibition of cell viability of methicillin resistant S. aureus was found to be 5% at 60 min. Membrane stabilization inhibitory gave 35.4 ± 0.67 µg/mL. EPSR3 has antitumor activity with a reasonable margin of safety. The antitumor activity of EPSR3 may be attributed to its content from uronic acids with potential for cellular antioxidant and anticancer functional properties. Full article
(This article belongs to the Special Issue Exploring Metabolic Adaptation of Microbials to Antibiotics)
Show Figures

Figure 1

Back to TopTop